BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts

被引：0
|
作者：
Yao, Sufei
Shang, Chengzhang
An, Gao
Guo, Chaoshe
An, W. Frk
Yang, Yi
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-2616
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A2616
引用
收藏
页数：2
相关论文
共 25 条
  • [21] Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer
    Cardillo, Thomas M.
    Sharkey, Robert M.
    Rossi, Diane L.
    Arrojo, Roberto
    Mostafa, Ali A.
    Goldenberg, David M.
    CLINICAL CANCER RESEARCH, 2017, 23 (13) : 3405 - 3415
  • [22] Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.
    Bardia, Aditya
    Diamond, Jennifer Robinson
    Messersmith, Wells A.
    Mayer, Ingrid A.
    Isakoff, Steven J.
    Abramson, Vandana Gupta
    Berlin, Jordan
    Starodub, Alexander
    O'Shaughnessy, Joyce
    Kalinsky, Kevin
    Moroose, Rebecca L.
    Shah, Nikita C.
    Juric, Dejan
    Shapiro, Geoffrey
    Guarino, Michael J.
    Ocean, Allyson J.
    Wilhelm, Francois
    Sharkey, Robert M.
    Goldenberg, David M.
    Vahdat, Linda T.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18)
  • [23] Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience
    Bardia, Aditya
    Vahdat, Linda T.
    Diamond, Jennifer Robinson
    Starodub, Alexander
    Moroose, Rebecca L.
    Isakoff, Steven J.
    Ocean, Allyson J.
    Berlin, Jordan
    Messersmith, Wells A.
    Thomas, Sajeve Samuel
    Wilhelm, Francois
    Wegener, William A.
    Maliakal, Pius P.
    Sharkey, Robert M.
    Goldenberg, David M.
    Mayer, Ingrid A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] Phase 1 study of the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors (JEWEL-101): Design of the triple-negative and hormone receptor-positive breast cancer expansion cohorts
    Ulahannan, Susanna
    Johnson, Melissa
    Weiss, Mia
    Vandross, Andrae
    Vidal-Cardenas, Sofia
    Syed, Mustafa
    Tolcher, Anthony
    CANCER RESEARCH, 2024, 84 (09)
  • [25] PPAB001, a novel bispecific antibody against CD47 and CD24, enhances anti-PD-L1 efficacy in triple-negative breast cancer via reprogramming tumor-associated macrophages towards M1 phenotype
    Yang, Yun
    Li, Jianqin
    Zhang, Jing
    Wu, He
    Yang, Yan
    Guo, Huaizu
    Zhang, Dapeng
    Ge, Chunpo
    Zhou, Bei
    Ma, Ling
    Dong, Weihua
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2025, 144
123